• Je něco špatně v tomto záznamu ?

Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis

A. Pinter, A. Reich, P. Arenberger, LS. Gold, A. Armstrong, L. Iversen, M. Praestegaard, M. Augustin

. 2023 ; 37 (11) : 2327-2335. [pub] 20230825

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000911

Grantová podpora
MC2 Therapeutics

BACKGROUND: The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well-established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL/BDP PAD-cream is an easily spreadable cream based on PAD TechnologyTM, an innovative formulation and drug delivery system. OBJECTIVES AND METHODS: A Phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8 weeks. The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD-cream as well as treatment acceptability compared to CAL/BDP gel and PAD-cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8. RESULTS: The percentage mean change from baseline to Week 8 in mPASI for CAL/BDP PAD-cream (67.5%) was superior compared to PAD-cream vehicle (11.7%; p < 0.0001) and non-inferior to CAL/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two-step improvement to clear or almost clear) after 8 weeks was superior for CAL/BDP PAD-cream (50.7%) compared to PAD-cream vehicle (6.1%, p < 0.0001) and statistically significantly greater than CAL/BDP gel (42.7%, p = 0.0442). Patient-reported psoriasis treatment convenience score (PTCS) for CAL/BDP PAD-cream was rated superior to CAL/BDP gel at Week 8 (p < 0.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL/BDP PAD-cream group compared to both PAD-cream vehicle (p < 0.0001) and CAL/BDP gel (p = 0.0110). Safety assessments during the trial demonstrated that CAL/BDP PAD-cream was well-tolerated. CONCLUSION: CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000911
003      
CZ-PrNML
005      
20240213093457.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.19330 $2 doi
035    __
$a (PubMed)37432045
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pinter, A $u Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany $1 https://orcid.org/0000000213301502
245    10
$a Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis / $c A. Pinter, A. Reich, P. Arenberger, LS. Gold, A. Armstrong, L. Iversen, M. Praestegaard, M. Augustin
520    9_
$a BACKGROUND: The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well-established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL/BDP PAD-cream is an easily spreadable cream based on PAD TechnologyTM, an innovative formulation and drug delivery system. OBJECTIVES AND METHODS: A Phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8 weeks. The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD-cream as well as treatment acceptability compared to CAL/BDP gel and PAD-cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8. RESULTS: The percentage mean change from baseline to Week 8 in mPASI for CAL/BDP PAD-cream (67.5%) was superior compared to PAD-cream vehicle (11.7%; p < 0.0001) and non-inferior to CAL/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two-step improvement to clear or almost clear) after 8 weeks was superior for CAL/BDP PAD-cream (50.7%) compared to PAD-cream vehicle (6.1%, p < 0.0001) and statistically significantly greater than CAL/BDP gel (42.7%, p = 0.0442). Patient-reported psoriasis treatment convenience score (PTCS) for CAL/BDP PAD-cream was rated superior to CAL/BDP gel at Week 8 (p < 0.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL/BDP PAD-cream group compared to both PAD-cream vehicle (p < 0.0001) and CAL/BDP gel (p = 0.0110). Safety assessments during the trial demonstrated that CAL/BDP PAD-cream was well-tolerated. CONCLUSION: CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.
650    _2
$a lidé $7 D006801
650    _2
$a fixní kombinace léků $7 D004338
650    12
$a psoriáza $x farmakoterapie $x chemicky indukované $7 D011565
650    _2
$a kalcitriol $x škodlivé účinky $7 D002117
650    _2
$a betamethason $x škodlivé účinky $7 D001623
650    _2
$a výsledek terapie $7 D016896
650    _2
$a emoliencia $x terapeutické užití $7 D004643
650    12
$a dermatologické látky $x škodlivé účinky $7 D003879
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Reich, A $u Department of Dermatology, University of Rzeszow, Rzeszów, Poland
700    1_
$a Arenberger, P $u Charles University, Prague, Czech Republic $1 https://orcid.org/0000000279199619 $7 xx0074761
700    1_
$a Gold, L S $u Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan, USA $1 https://orcid.org/0000000227581605
700    1_
$a Armstrong, A $u University of Southern California, Los Angeles, California, USA
700    1_
$a Iversen, L $u MC2 Therapeutics, Hørsholm, Denmark
700    1_
$a Praestegaard, M $u MC2 Therapeutics, Hørsholm, Denmark
700    1_
$a Augustin, M $u University Medical Center Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000240268728
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology $x 1468-3083 $g Roč. 37, č. 11 (2023), s. 2327-2335
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37432045 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093454 $b ABA008
999    __
$a ok $b bmc $g 2049498 $s 1210605
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 37 $c 11 $d 2327-2335 $e 20230825 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
GRA    __
$p MC2 Therapeutics
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace